Previous 10 | Next 10 |
2023-11-07 16:39:19 ET More on Xencor Xencor: Data In Early 2024 Could Bring Shareholder Value Xencor: A Mid-Stage Clinical Company With Falling Losses Xencor finance chief to step down Vir Biotech nabs $50M BARDA funding to discover antibody therapies ...
-- Royalty Transaction Generates $215 Million Upfront -- -- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and a...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion Pharmaceuticals, Inc., on sales of Ultomiris ®...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Xencor Inc. (XNCR) is expected to report $-0.77 for Q3 2023
2023-11-06 13:53:32 ET Xencor ( NASDAQ: XNCR ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, after market close. The consensus EPS Estimate is -$0.71 and the consensus Revenue Estimate is $30.03M (+10.0% Y/Y). Over the last 3 months, EPS estima...
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented data from multiple preclinical-stage XmAb ® programs at the 38th Annual Meeting of the Society for I...
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023. ...
2023-10-27 11:56:53 ET Summary Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate shareholder value. The global metastatic castration-resistant prostate cancer treatment market is expe...
2023-10-26 10:50:51 ET More on Xencor Xencor: A Mid-Stage Clinical Company With Falling Losses Vir Biotech nabs $50M BARDA funding to discover antibody therapies Seeking Alpha’s Quant Rating on Xencor For further details see: Xencor finance chief t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through ...
2024-06-04 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...